Avacta to Host Therapeutics Division Science Day

RNS Number : 0781K
Avacta Group PLC
19 December 2022
 

 

 

19th December 2022

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Avacta to Host Therapeutics Division Science Day on 23rd February 2023

 

Science Day to include presentation of the data emerging from the phase 1a clinical trial of AVA6000

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will host a Science Day for City analysts and fund managers on 23rd February 2023 to discuss recent progress within the Company's Therapeutics Division and hear from selected key opinion leaders in the field of oncology.

 

The event will include an update on the ongoing preclinical programmes as well as on progress in the ALS-6000-101 phase 1a clinical trial of AVA6000, Avacta's lead pre|CISIONTM tumour targeted chemotherapeutic, a modified form of the chemotherapy doxorubicin.

 

The Company will update the Market on progress in this study in early January 2023, in advance of the Science Day.

 

A recording of the presentations will be available after the event on Avacta's website www.avacta.com .

 

 

-Ends-

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

Michael Vinegrad, Group Communications Director

 

Tel: +44 (0) 1904 21 7070

www.avacta.com

Stifel Nicolaus Europe Limited (Nomad and Broker)

Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares / William Palmer-Brown

 

Tel: +44 (0) 207 710 7600

www.stifel.com

FTI Consulting (Financial Media and IR)

Simon Conway / Alex Shaw / George Kendrick

 

Tel: +44(0) 203 727 1000

Avacta.LS@fticonsulting.com

Zyme Communications (Trade and Regional Media)

Lily Jeffery

 

Tel: +44 (0)7891 477 378

lily.jeffery@zymecommunications.com

 

About Avacta Group plc - https://www.avacta.com

 

Avacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics.

 

Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer ® immunotherapies and pre|CISIONTM tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programmes in the pipeline as well as several global research collaborations and licensing partnerships. Avacta's lead programme, AVA6000, is a pre|CISIONTM tumour-targeted form of the established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in patients with locally advanced or metastatic selected solid tumours.

 

The Affimer® platform is an alternative to antibodies that has been designed to address many of the drawbacks of antibodies which, despite their shortcomings, currently dominate the immuno-diagnostics and immuno-therapeutics markets.

 

The pre|CISION™ tumour targeting platform can be used to modify a chemotherapy in order to selectively release the active drug in tumour tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre|CISION™ modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.

 

Avacta's Diagnostics Division develops and supplies a broad range of in-vitro diagnostic (IVD) solutions for healthcare professionals and consumers. The Division is growing rapidly through an M&A strategy to deliver a global scale IVD business providing market leading solutions for healthcare professionals and consumers to inform treatment and monitor health and well-being. In October 2022, Avacta acquired Launch Diagnostics which serves the hospital pathology laboratory market in the UK and Europe. Avacta Diagnostic's research and development centre in Wetherby, UK uses its proprietary Affimer® platform to differentiate immunodiagnostic products to provide marketing leading performance.

 

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFFSIFFLTLIF
UK 100

Latest directors dealings